HMGCoA还原酶(HMGCoa reductase)是胆固醇合成的限速酶，存在于小胞体膜，催化合成甲基二羟戊酸(mevalonic acid)，并生成体内多种代谢产物，称之为甲基二羟戊酸途径。细胞内胆固醇水平调节主要信赖于内因性胆固醇合成途径和LDL受体摄取细胞外胆固醇的外因途径两条。Goldstein ,Brown阐明其抑制机制认为，细胞内ch作为HMGCoA还原酶抑制剂使其活性降低，肝细胞膜上的LDL受体增加，从血中摄取ch增加，使血中胆固醇水平降低，设想HMGCoA还原酶活性降低的药物可使血中胆固醇水平下降，尤其是对FH的杂合子患者，LDL受体数锐减者可起治疗作用。
Kovanen等报导以merinolin的HMGCoA还原酶抑制剂投入，使狗血中LDL消失速度上升，LDL产生速度下降，肝移植的小儿FH纯合子患者，用梅维诺林治疗可使LDL胆固醇降低40%，而LDL产生速度下降35%，LDL合成减少的机制，有两种可能，一是胆固醇合成减少使VLDL生成量降低；第二是HMGCoA还原酶抑制剂使VLDL残粒或βVLDL异化增加，转变成LDL减少，体外实验也证实，从VLDL残粒到LDL的速度比正常状态下小20倍，与此同时LDL受体的亲和力也增加。
仓鼠HMGCoA还原酶基因长30kb，由20个外显子组成，在启动子5'端富含GC碱基。HMGCoA还原酶，从转录水平作为胆固醇代谢的调节点，与LDL受体基因启动子，HMGCoA合成酶，从转录调节域存在有相同的碱基系列，即CACCCC(或GT)AC的胆固醇调节元件(sterol regulatory element,SRE)存在，如图5-5所示。
图5-5 胆固醇代谢调节的启动子与SRE
第一条线的数字为从转录开始的距离(碱基对数)
(董学梅)
参 考 文 献
1.杨振华，酶的测定，见：叶应妩，李健斋，王玉琛主编。临床实验诊断学，北京：人民卫生出版社，1991，588～466
2.Paltarf F,Wagner E,Stereospecificity of Lipase enzymatic hydrolyosis of enantiomeric aldyldiacyl and dialdylacylglyerols by lipoprotein lipase.Biochim Biophys Acta,1976,431:359-362
3.Deeb SS.Peng R.Structure of the human lipoprotein lipase gene .Biochemistry,1989,1169:582-4134
4.Gotoda T,et al.Anewly identified null allelic mutation in the human lipoprotein lipase(LPL)gene of a compornd heterozygote with familial LPL deficienacy,Biochys Acta,1992,1169:582-586
5.Okabe T,Yorifaji H,et al .Pulmonary macrophage:Amajor source of lipoprtein lipase in the lung.Biochim Biophys Res Commun,1984,125:273-278
6.Oka K,George T,Stocks J,et al.Nucleotide sequence of PvuⅡpoolymorphic site at the human lipoprotein lipase gene locus .Nuceic Acids Research,1990,18:5407-5411
7.Chuat J,Raisonnier A,Etienne J,et al.The lipoprotein lipase-encodigng human gene:sequence from intron-6 to intron-9 and presence in intron-7 of a 40-million-year-old Alu sequence.Gene,1992,110:257-261
8.Gotoda T,Yamada N,Murase T,et al .Detection of three separate DNA polymorphisms in the human lipoprotein lipase gene by gene amplfication and restriction endonuclease digestion.J Lipid Res,1992,33:1067-1072
9.Raj K,Edward W,Ruth M,et al .DNA variants at the LPLgene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a welsh poprlation.Arteriosclerosis and Thrombosis,1994,14:1090-1097
10.Robert A,Andrew J,Liling T,et al .Agene-gender interaction affecting plasma lipoproteins in a genetic isoalate,Arteriosclerosis and Thrombosis,1994,14671-677
11.Yang C,et al.Lecithin:cholesterol acyltransferase.J Biol Chem,1987,262:3086-3091
12. Alberts J,Adolphson J,Chen C,et al.Radiommunoassay of human plasma lecithin cholesterol acyltransferase.J Clin Invest,1981,67:141-148
13.Mclean J et al .Cloning and expression of human lecithin cholesterol transferase cDNA ,Proc Natl Acad Sci USA ,1986,83:2335-2339
14.Glomset .J.Norum K,Gjone E,et al.Lecithin:cholesterol acyltransferase deficiency.In:The Metabolic Basis of Inherited Disease.McGraw Hill ,New Youk,1983,643-654
15.Glomset J.The plama lecithin cholesterol acyltransferase reaction.J Lipid Res,1968,9:156-167
16.Holmqusit Z,Carlson L.Normalization of high density lipoprotein in fish eye disease plasma by purified normal human lecithin cholesterol acyltransferase .Lipids ,1988,23:225-229
17.Zilversmit D B.Atherogenic nature of triglycerides .postprandial lipidemia and triglyceride-rich remnant.Clin Chem,1995,41:153-158
18.Takagi A, et al.Molecular strdies on primary lipoprotein lipase(LPL)deficiency:one base deltion (G916)in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPLmessenger RNA transcript.Jclin Invest,1992,41:153-158
19.Jingami R,Brown M,Goldstein J,et al .Partial deletion of membrane-bound domain of 3-hydroxy-3methylglu-taryl coenzyme a reductase eliminates sterol enhanced degradation and prevents formation of crystalloid endoplasmic reticulum,Jcell Biol,1987,104:1693
20.Goldsteir J,Brown M,Regulation of the mevalonate pathway.Nature ,1990,343:425-430
21.East C,Grundy S,Bilheimer D,et al.Preliminary report:Treatment of ytpe 3 hyperlipidemia with mevinolin.Metabolism,1986,35:97098-,104:1693
22.阵上久人，HMGCoa Reductaseとそのinhibiter .最新医学，1992，47：82-90
, 百拇医药